Allergan Pays $2bn-Plus For Zeltiq, Expanding Aesthetics Business
Zeltiq's CoolSculpting body-contouring system will be the third "pillar" in Allergan's aesthetics business, along with its existing facial aesthetics and plastic and regenerative surgery lines, the company says.
You may also be interested in...
Abbvie Sculpts Position In Aesthetics Space With Allergan Acquisition
Abbvie is taking on Allergan's aesthetics portfolio as part of its $63bn takeover deal. The acquisition includes Allergan's CoolSculpt body contouring system and a new FDA-approved device for muscle strengthening.
Allergan Aesthetic Medicines Head Moatazedi Moves To Emerging Competitor Evolus
David Moatazedi is leaving behind the aesthetic medicines group at Allergan to run the newly public, aesthetics-only firm Evolus, where US and EU approval of the Botox competitor DWP-450 (prabotulinumtoxinA) is imminent and the new CEO says the opportunity is unparalleled.
Atlantic Therapeutics Appoints Former Zeltiq CEO As Chairman
Atlantic Therapeutics has appointed former Zeltiq Aesthetics CEO Gordie Nye as its new chairman to help drive adoption of its CE-marked Innovo device for treating clinical conditions associated with pelvic floor weakness.